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The concept of delaying or preventing epithelial transformation remains a viable and attainable goal for the future. Drug-based
strategies for chemoprevention of the future may predominantly rely upon targeted therapies with tolerable but defined toxicities for
treatment of individuals diagnosed with intraepithelial neoplasias. Foods, diet manipulation strategies, or nutraceuticals may be more
appropriate to delay or prevent carcinogenesis progression in healthy populations with genetic or epidemiologic evidence of risk for
future transformation.
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Three recent publications have demonstrated an unacceptable
therapeutic index due to cardiovascular toxicity of selective
cyclooxygenase-2 inhibitors when used for cancer preventive or
anti-inflammatory indications (Bresalier et al, 2005; Nussmeier
et al, 2005; Solomon et al, 2005). These data have focused the
debate on whether pharmacologic interventions aimed at delaying
or preventing the transformation of organ epithelia should
proceed. Further, bad news for proponents of the cancer
chemoprevention approach emerged recently from a trial of a-
tocopherol supplements in patients with stage I or II head and
neck cancer treated by radiation therapy (Bairati et al, 2005). In
these patients, the incidence of second primary cancers was higher
(hazard ratio: 2.88) than that in patients who received the placebo.
The corollaries of these clinical results have been amply debated
(for example, see Alberts et al, 2005; Drazen, 2005; Meyskens and
Szabo, 2005). In this minireview, we wish to distill some crucial
issues from that debate, and re-evaluate current and prospective
chemoprevention strategies considered promising in the light of
these issues.
The recent cancer chemoprevention trial experiences have
directed the focus on the following four pivotal issues:
(1) Acceptable therapeutic index for interventions in healthy
populations: Individuals who are treated for a full-blown
malignancy accept toxic therapies as a price for improved quality
of life, survival, or both. In contrast, the acceptable therapeutic
index for interventions intended for healthy individuals at risk of
cancer in the future has ‘y been both underestimated and
overestimated from failure to critically assess the parameter in
relation to the modulation of the relevant biologic/biochemical/
molecular end-points’ (Meyskens and Szabo, 2005).
In the case of cardiovascular disease prevention, the individuals
and physicians accept treatment-induced toxicity if the recipient is
convinced that a ‘disease’ such as hypertension or hvpercholester-
olemia is being treated. In the case of neoplastic risk, healthy
individuals at high risk for future development of a malignancy,
for example, individuals with highly penetrant, low-frequency
mutations (e.g. BRCA, familial adenomatous polyposis), are
usually willing to tolerate surgical procedures such as colectomy,
mastectomy, and oophorectomy to reduce cancer risk. Irritating,
yet minor, adverse effects (e.g. hypokalemia associated with
diuretics, headaches) are less acceptable for intervention in
healthy populations, who are not ‘diagnosed’ with clear and
imminent ‘disease’, but rather are approached to undergo an
intervention on the basis of a conceptually abstract ‘epidemiologic
risk profile’. Major toxicities such as the recently reported
enhanced risk of cardiovascular events associated with the
administration of cyclooxygenase-2 inhibitors are unacceptable
for any intervention with chemopreventive intent. While these
examples represent opposite ends of a continuum of risk–benefit
for chemopreventive intervention, risk–benefit for the bulk of
individuals at risk for sporadic neoplasms is less clear and poorly
defined.
(2) Existence of preliminary data to rationalise trials in humans:
Epidemiologic data, that is, hypotheses-generating associations,
have not accurately predicted prospective cancer preventive
outcomes to date with sufficient certainty to justify large-scale,
high-cost trials with a cancer end-point (Meyskens and Szabo,
2005). Rodent models of carcinogenesis, either transgenic or
chemically induced, provide tools to probe carcinogenesis
mechanisms and to obtain preliminary evidence of potential
preventive efficacy (Hawk et al, 2005). Nevertheless, the knowledge
accrued thus far in such models suggests that their usefulness to
predict therapeutic indices of cancer chemopreventive agents is
rather doubtful (Corpet and Pierre, 2003).
(3) Trial design and progression of research in humans: The
mixed record of success of the development of novel chemical
entities by the pharmaceutical industry as cancer chemopreventive
drugs points to the importance of design, implementation, and
interpretation of phase I and II research in humans. An optimal
cancer preventive dose cannot be extrapolated from doses used for
different therapeutic indications. For example, in the chemo-
prevention of colorectal adenocarcinomas, higher doses of aspirin
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cardiovascular disease (Baron et al, 2003). Recent discussions have
emphasised the importance of studying fundamental dose–
response relationships in the field of cancer chemoprevention
followed by extended biomarker-driven phase II efficacy trials in
humans prior to embarking upon large, long, costly phase III risk
reduction trials with cancer end-points (Alberts et al, 2005;
Meyskens and Szabo, 2005).
(4) Importance of biomarkers as potential surrogates for
preventive efficacy: Meyskens and Szabo (2005) cogently described
the conceptual, syntactic, and scientific confusion currently
surrounding biomarkers as potential chemoprevention end-points.
Nevertheless, future definition of therapeutic efficacy of interven-
tions designed to delay or prevent neoplastic progression requires
discovery and validation of genetic or biochemical processes that
reliably reflect the future potential of target epithelia to progress
towards transformation. Current efforts by the US National Cancer
Institute (NCI) to support and systematise biomarker discovery,
validation, and application through the Early Detection Research
Network (EDRN) (Verma and Srivastava, 2003) and Specialized
Organ Research Effort (SPORE) mechanisms provide the necessary
complex infrastructure. While splitting the development and
validation of biomarkers from measurement of efficacy of
preventive intervention reduces the rate of progress during the
short term, such efforts will enhance the quality and speed of
translational progress of new intervention products for preventive
indications in the long run.
One might conclude that efforts to develop new chemopreven-
tive interventions should be de-emphasised, and that resources
should be redirected to more fundamental research. The
experience gained in cancer chemoprevention trials to date
provides important lessons that suggest a more rational, scienti-
fically driven mode of development than that which has been often
pursued until now. This process should enable a systematic,
stepwise, phased exploration in preclinical models and in humans
of newly emerging interventions. In the light of these considera-
tions, we discuss below a chemopreventive agent selection strategy
of novel drugs and a number of specific agents with putative
cancer chemopreventive potential, of which some are currently
under active clinical investigation and others originate from novel
sources still at the stage of preclinical development.
PREVENTIVE AGENT SELECTION FOR
DEVELOPMENT IN HUMANS
The recent experiences gained in the development of drugs as
cancer chemopreventive agents lead to the conclusion that the
therapeutic index of proposed interventions should be titrated to
relative risk of transformation. Individuals at high risk of
developing malignancies with proven pathological evidence of
potential transformation (‘intraepithelial neoplasia’), for example
individuals with adenomatous polyps, atypical ductal hyperplasia,
or oral leukoplakia, might be considered suitable candidates for
‘treatment of their disease’ using interventions consisting of single
or combined drug-based approaches. Optimally, such drugs
should target specific molecular carcinogenesis profiles obtained
via genetic or proteomic profiling of that individual’s pathologic
lesion. Drugs that target intracellular regulation of proliferation,
survival, and angiogenesis may be suitable to be used in such
individuals with preneoplasias as compared to those who suffer
from advanced full-blown malignancies (i.e. transformed, invasive
cancers). Such an approach might start with small, rapidly
implemented and brief (60 days or less) translational clinical
trials of biomarker modulation by multiple doses of a given
intervention, alone or in combination with other mechanism-
based agents. Subsequent biomarker-driven trials of drug combi-
nations require duration of a year or more to assess both toxicity
and continued biomarker effects prior to consideration of large,
population-based cancer end-point trials. Toxicity profiles should
include quality of life instruments to reflect the potential adverse
nature of such interventions (Stanton et al, 2005).
Strategies for the prevention of malignancies in patients at
higher than normal risk of developing cancer but without evidence
of pathologic progression can exploit concepts established in the
treatment of cardiovascular risk factors. Hypertension and
hypercholesterolaemia are considered ‘diseases’ that are treated
by physicians despite the fact that these end-points are biomarkers
for future cardiovascular events. Critical to the future implementa-
tion of cancer preventive interventions using drugs are the ability
to alter public opinion and to prompt primary medical care
providers to adjust their perception concerning high-risk cancer
biomarkers – in analogy to treatment of cardiovascular biomarkers
– and willingness to accept mild toxicity. For such individuals, a




Nonsteroidal anti-inflammatory agents (NSAIDs)
In the wake of the recent observations of unacceptable cardio-
vascular effects of selective cyclooxygenase-2 inhibitors, and
mindful of the long-known gastro-intestinal irritation/damage
associated with long-term consumption of NSAIDs, is this class of
agent still viable as potential cancer chemopreventive intervention?
We maintain that it is. Firstly, the epidemiological evidence that
regular use of NSAIDs, such as aspirin, reduces cancer risk in a
number of organs, especially the colorectum, is overwhelming,
and it clearly supports the notion that cyclooxygenase inhibition
has antineoplastic consequences (Thun et al, 2002). Secondly,
prospective, randomised clinical trials using an intraepi-
thelial neoplasia end-point suggest that two different NSAIDS,
aspirin and sulindac, reduce recurrence of adenomatous polyps
(Giardiello et al, 1993; Baron et al, 2003).
It is important to note that cyclooxygenase-independent
mechanisms of action of NSAIDs may, at least in part, explain
their anticancer activity (Thun et al, 2002). For example, the
selective cyclooxygenase-2 inhibitor celecoxib has been demon-
strated to inhibit AKT signalling and to induce apoptosis of human
colorectal and prostate cancer cells in vitro in a cyclooxygenase-
2-independent manner, by a mechanism involving direct inhibi-
tion of phosphoinositide-dependent kinase-1 (PDK-1) (Arico et al,
2002; Song et al, 2002). Whether this activity is relevant to the
antineoplastic activity of celecoxib in vivo is unclear at present.
Currently, a number of clinical trials of the chemopreventive
efficacy of the selective cyclooxygenase-2 inhibitors remain in
analysis for colorectal adneocarcinoma, transitional cell carcinoma
of the bladder, breast adenocarcinoma, cervical intra-epithelial
neoplasia, lung cancer, skin cancer, and oral leukoplakia. While
many of these trials have been disrupted following recognition of
the cardiovascular toxicity of selective cyclooxygenase-2 inhibitors
(Bresalier et al, 2005; Solomon et al, 2005), nevertheless, useful
data will emerge from these studies, which will ultimately define
the chemopreventive efficacy of these agents (Alberts et al, 2005).
A more rigorous dose–response evaluation to ascertain the
optimal dose and schedule required to delay or prevent cellular
transformation may enable the use of lower doses that might not
cause cardiovascular toxicity.
Molecular targeted approaches other than cyclooxygenases
ErbB tyrosine kinases, the most prominent among them being
epidermal growth factor receptor (EGFR), when phosphorylated
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motility, and proliferation. Inhibitors of EGFR activation via
antibodies to the extracellular protein or via tyrosine kinase
inhibitory molecules provide promising new approaches to both
cancer treatment and prevention. Despite mixed results in cancer
treatment, many dysplastic cells also have activated EGFR and are
reasonable targets for these agents. Preclinical data in vitro and in
vivo support the potential preventive efficacy of these agents,
potentially in combination with NSAIDs for chemoprevention of
colorectal and head and neck cancers (Shin et al, 1994).
P53 targeting with ONYX-015, an adenovirus that replicates only
in p53-deficient cells, produced histologic resolution of dysplasis
in seven of 19 patients with oral leukoplakia (Rudin et al, 2003).
Other p53-deficient dysplasias or high-risk epithelial fields might
be protected with this agent.
Peroxisome proliferation activated receptor (PPAR) gamma
agonists, such as rosiglitazone, are currently in early phase
chemoprevention development. These agents are of particular
interest for targeting hormone receptor negative breast epithelial
proliferations or dysplasia (Mehta et al, 2000).
Hypermethylation contributes to carcinogenesis by silencing
downstream transcription of key tumour suppressor genes. That
aging and carcinogenesis are linked through progressive changes
in methylation patterns of key tumour suppressor genes suggests
potential future chemoprevention targets. Pharmacologic inhibi-
tion with well-tolerated interventions that inhibit or reduce activity
of methyltransferase and histone deacetylase proteins may reduce
abnormal hypermethylation of key tumour suppressor gene
promoters, thus reducing or delaying neoplastic transformation.
Hydralazine is one potentially useful DNA methylation inhibitor
(Deng et al, 2003). A number of synthesised hydroxamic acid
inhibitor of histone deacetylase inhibitors are currently in clinical
trials for cancer treatment (Marks et al, 2000).
Combined agents
The complexity and heterogeneity of known carcinogenesis
mechanisms provides a strong rationale for combining drug
interventions that might provide additive or synergistic anti-
carcinogenesis effect. In addition to targeted anticarcinogenic
mechanism-based approaches, population epidemiology and
rodent models help in the choice of suitable agents for
combinations. The most quoted example under investigation, the
combination of inhibitors of EGFR signalling and cyclooxygenase
(Torrance et al, 2000), which is currently under investigation in
humans, may be modified due to the recent therapeutic index
concerns for targeted cyclooxygenase inhibitors. Data in vitro and
in vivo support the viability of combining HMG CoA reductase
inhibitors and NSAIDs to increase apoptosis via enhanced caspase
3 activity in preneoplastic cells (Agarwal et al, 1999). DFMO and
sulindac are currently in phase IIb clinical trial as a potential
colorectal adenocarcinoma preventive combination (Gerner and
Meyskens, 2004).
PREVENTION OF SPORADIC EPITHELIAL NEOPLASIA
IN POPULATIONS WITHOUT HIGH-RISK LESIONS
A population-based approach to chemopreventive intervention
considers the gene–environmental risk of otherwise healthy
populations. For example, individuals with high-frequency, low-
penetrance polymorphisms such as the adenomatous polyposis
coli II307K polymorphisms have a higher risk of developing
colorectal adenocarcinoma, but this risk does not appear to
become clinically apparent until later in life (Niell et al, 2003).
Interventions or behaviour expected to reduce transformation risk
have amplified protective effects in this cohort when compared to
lower risk populations (Poynter et al, 2005).
One may consider the I1307K polymorphism as a paradigm for
other single nucleotide polymorphisms associated with enhanced
transformational risk. Otherwise healthy individuals who are
found to carry such polymorphisms would reject high-cost, mildly
toxic pharmaceutical interventions but might be receptive to
dietary interventions or nutriceutical interventions.
Nutriceuticals
Could there be ‘nontoxic alternatives’ to drugs with unacceptable
therapeutic indicies such as NSAIDs or targeted therapeutic
agents? Some recent results tentatively suggest that certain
nutriceuticals may constitute such an alternative. Considerable
evidence supports the hypothesis that flavonoids and other
polyphenolic phytochemicals contained in certain foodstuffs, for
example onions, red grapes, nuts and green tea, mediate, or
contribute to, the putative cancer chemopreventive properties of
their dietary sources. One potential approach is to deliver
chemopreventive substances as a food supplement that is grown
consistently between years to deliver constant concentrations of
micronutrients. For example, black raspberries, which contain
substantial concentrations of phenolic acids such as ellagic acid
and ferulic acid, flavonoids such as anthocyanins, vitamins and
minerals, may be grown with standardized content within and
between years. When tested in rodent models, freeze-dried and
frozen formulations of black raspberries inhibit colon tumours and
aberrant crypt foci at concentrations of individual anticarcinogen-
esis constituents that are 10-fold less than the concentration of
each individual constituent necessary to block aberrant crypt foci
when given as a purified product (Harris et al, 2001). A whole
food, given fresh or freeze dried as a capsule, containing multiple
components thought to be anticarcinogenic is an efficient,
nontoxic delivery system for potential anticarcinogenic com-
pounds.
Alternatively, purified chemical isolates of foodstuffs may also
be useful as preventive ‘drugs’. Such purified substances are
commonly ingested in the food supply, sometimes in substantial
quantities. Examples of such agents are curcumin, a constituent of
curry, and resveratrol, contained in red grapes and berries. A
plethora of mechanistic studies in cells in vitro suggests that
polyphenolic phytochemicals can undermine oncogenic signalling
cascades germane to tumour promotion and progression in a
variety of ways (Manson et al, 2005). Both curcumin and
resveratrol interfere with the cyclooxygenase-catalysed production
of prostanoids from arachidonic acid by downregulation of
arachidonic system catabolic enzymes (cyclooxygenases and
lipoxygenases) and can reduce cancers in multiple rodent model
systems of epithelial tumours (Leu and Maa, 2002; Aggarwal et al,
2004).
In the light of issue 2 outlined in the introduction, it seems most
important to find out whether the potency difference in rodent
colonic carcinogenesis models between NSAIDs and polyphenolic
phytochemicals (Gescher, 2004) translates into a similar difference
in the ability to achieve adenoma regression in humans.
Alternatively, it is conceivable that efficacy in rodent models just
‘signals’ potential for activity in humans without potency
implications, implying that a positive result for an intervention
in the preclinical model renders its preliminary investigation in
humans definitely worthwhile.
Diet modification
Diets rich in fruits and vegetables, specifically diets rich in citrus
fruits, dark green vegetables, and cruciferous vegetables, reduce
risk of cancer. Recent data document success in diet modification
using extensive prepared materials, staff effort, intensive inter-
vention with the targeted population over a 1-year (Resnicow et al,
2001; Pierce et al, 2004) or 4-year period (Schatzkin et al, 2000).
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2000; Resnicow et al, 2001; Pierce et al, 2004) and medically
underserved populations (Resnicow et al, 2001). The entire diet
can be modified to enhance fruit and vegetable intake (Schatzkin
et al, 2000; Resnicow et al, 2001; Pierce et al, 2004). Dietary
interventions utilising motivational interviewing performed by
minimally trained lay members of a community can successfully
disseminate cancer protective diets to large populations at minimal
cost (Resnicow et al, 2004).
A prospective, 4-year diet modification trial failed to
reduce adenoma recurrence (Schatzkin et al, 2000). Similarly,
an intervention with fibre also failed to reduce colorectal
adenoma recurrence (Alberts et al, 2000) The former trial was
criticised because the serum biomarker of diet modification,
serum carotenoids, did not change in the treated group while
the dose and type of fibre used was criticised in the later trial.
The ongoing WHEL project (Pierce et al, 2004) tests the question
of dietary modulation impact upon cancer preventive and
treatment efficacy in a population of women with early-
stage breast cancer (Pierce et al, 2004). The tools and pro-
cedures necessary to effect a dietary change in a large
population (thousands) are available at reasonable cost. While
attempts to modify human carcinogenesis with diet modification
to date have been disappointing, the effects of these interventions
may require much longer term follow-up (beyond 4 years).
Alternatively, intervention prior to the appearance of a late
carcinogenesis neoplastic event, such as a dysplastic lesion, in
individuals with low-penetrance, high-frequency genetic haplo-
types predictive for increased risk of an epithelial cancer may be
required to demonstrate cancer preventive efficacy. Given the low
toxicity, low cost, and relative ease of implementation, diet
modification should be considered as a preferred preventive
intervention in the healthy but a higher than normal risk
population.
SUMMARY
Recent publications have identified major weaknesses in the
developmental strategies of cancer chemopreventive agents that
have resulted in negative trial outcomes. Pivotal issues have
included (1) concerns over the concept of acceptable therapeutic
index for interventions in healthy populations; (2) the necessary
preliminary data set required to support the development and
implementation of research in humans; (3) the design and
progression of research in humans aimed at defining preventive
efficacy; and (4) the discovery and validation of biomarkers as
potential surrogates for preventive intervention efficacy. Addres-
sing these issues requires reorientation of the selection process of
individuals at risk for a future cancer. Individuals at high risk for
future transformation are more likely to accept the toxicity risks
and financial costs of treatment-related toxicity in exchange for
delay of cancer occurrence. Individuals without a known tissue or
molecular high-risk factor for cancer will not tolerate toxicity that
reduces quality of life.
To address these two groups, which represent opposite poles of
a risk continuum, development of multiagent pharmacologic
interventions for high-risk individuals is warranted. Future
combinations of pharmaceutical cancer preventives might consist
of agents targeted to specific signal transduction pathways
associated with specific epithelial cellular targets. Diet modifica-
tion, and food or nutritional extracts (‘nutriceuticals’) with known
anticarcinogenesis activity may be more acceptable to healthy
populations with known genetic risk based upon gene–environ-
ment interactions.
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